PTC had their first investor conference yesterday, here is a brief summary:
- Second phase 3 Ataluren study planned to start in the first half of 2014 with CF nonsense mutations
- Plan to apply to the EMA (Europe) this year
- Potential for combination with Vertex's Kalydeco discussed during investor conference, PTC looking at ways to evaluate this concept
More info here: http://sixtyfiverosesblog.wordpress.com/2013/08/13/august-ataluren-update/
- Second phase 3 Ataluren study planned to start in the first half of 2014 with CF nonsense mutations
- Plan to apply to the EMA (Europe) this year
- Potential for combination with Vertex's Kalydeco discussed during investor conference, PTC looking at ways to evaluate this concept
More info here: http://sixtyfiverosesblog.wordpress.com/2013/08/13/august-ataluren-update/